List of Excipients in Branded Drug SENSIPAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	SENSIPAR	cinacalcet hydrochloride	50090-3529	CARNAUBA WAX
A-S Medication Solutions	SENSIPAR	cinacalcet hydrochloride	50090-3529	CELLULOSE, MICROCRYSTALLINE
A-S Medication Solutions	SENSIPAR	cinacalcet hydrochloride	50090-3529	CROSPOVIDONE

Sensipar Excipient Strategy and Commercial Opportunities for Cinacalcet

Last updated: August 2, 2026

Sensipar is the branded form of cinacalcet hydrochloride, an oral calcimimetic approved for secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, hypercalcemia in parathyroid carcinoma, and severe hypercalcemia in primary hyperparathyroidism when surgery is not appropriate. The product is a conventional immediate-release film-coated tablet in 30 mg, 60 mg, and 90 mg strengths.[1]

The commercial opportunity is primarily generic and reformulation-driven. Core U.S. composition-patent protection has expired, and cinacalcet is a small molecule exposed to conventional ANDA competition rather than biosimilar competition. Excipient development should focus on dissolution, dose uniformity, tablet robustness, swallowability, and manufacturing cost. A differentiated product could target lower pill burden, improved tolerability, pediatric administration, or markets where dialysis clinics and hospital formularies prioritize reliable supply.

What is Sensipar and how does cinacalcet work?

Cinacalcet increases the sensitivity of the calcium-sensing receptor on parathyroid cells to extracellular calcium. This reduces parathyroid hormone secretion and lowers serum calcium and phosphorus-related disease burden in appropriate patients.[1]

Attribute	Sensipar
Active ingredient	Cinacalcet hydrochloride
Therapeutic class	Calcimimetic
Dosage form	Immediate-release film-coated tablet
U.S. strengths	30 mg, 60 mg, 90 mg
Original sponsor	Amgen
U.S. NDA	021688
Initial FDA approval	March 8, 2004
Main markets	Dialysis-related secondary hyperparathyroidism, parathyroid carcinoma, severe primary hyperparathyroidism
Generic pathway	ANDA, 505(j)
Biosimilar pathway	Not applicable

Cinacalcet has historically been administered with food because food increases exposure. The FDA label instructs patients to take Sensipar with food or shortly after a meal.[1] That requirement creates a product-development constraint: an excipient system that changes dissolution or absorption substantially could create bioequivalence and labeling risks.

What excipients are used in Sensipar tablets?

The U.S. Sensipar label identifies a conventional tablet excipient system. Listed inactive ingredients include colloidal silicon dioxide, crospovidone, ferric oxide yellow, hypromellose, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, and titanium dioxide.[1]

Excipient or coating component	Likely formulation function
Microcrystalline cellulose	Diluent, compressibility, tablet structure
Pregelatinized starch	Binder and disintegration support
Povidone	Binder
Crospovidone	Superdisintegrant
Colloidal silicon dioxide	Glidant and powder-flow aid
Magnesium stearate	Lubricant
Hypromellose	Film-forming coating polymer
Titanium dioxide	Opacifier and pigment
Ferric oxide yellow	Colorant

The formulation is commercially important because cinacalcet presents practical development challenges. The drug is administered at relatively low tablet strengths but has low aqueous solubility and clinically relevant food effects. Excipients must support rapid and reproducible drug release without creating excessive batch-to-batch variability.

What excipient strategy is appropriate for generic cinacalcet?

A conventional Q1/Q2-equivalent immediate-release formulation is the lowest-risk strategy for an ANDA. The generic sponsor should begin with a formulation close to the reference product's qualitative and quantitative excipient profile, then optimize within the boundaries of the FDA product-specific expectations and comparative dissolution data.[2]

Priority 1: Control dissolution and disintegration

Crospovidone, pregelatinized starch, and microcrystalline cellulose provide a standard disintegration platform. The key development variables are:

• Crospovidone concentration and intra-granular versus extra-granular placement.
• Granulation moisture and endpoint.
• Tablet hardness and friability.
• Magnesium stearate concentration and lubrication time.
• Particle-size distribution of cinacalcet hydrochloride.
• Coating weight gain and coating uniformity.

Over-lubrication can slow wetting and dissolution. Excessive compression force can create hard tablets that fail rapid-release targets. A design-of-experiments program should link these variables to dissolution across acidic and near-neutral media.

Priority 2: Manage low-solubility risk

Potential formulation tools include:

• Reduced particle size or micronized active ingredient.
• Spray-dried or hot-melt dispersion systems.
• Surfactant-assisted wetting.
• Amorphous polymer systems.
• Co-crystal or salt-form screening.
• Lipid-based systems for non-ANDA reformulation products.

For a standard ANDA, complex enabling technologies may increase regulatory and manufacturing risk without producing a commercial advantage. They become more attractive for a differentiated 505(b)(2) product, a pediatric formulation, or a product designed to reduce food dependence.

Priority 3: Improve tablet handling and swallowability

Dialysis patients often take multiple medicines, and cinacalcet may contribute to nausea and vomiting. A smaller tablet, lower tablet weight, smoother film coating, or optimized debossing can improve usability without changing the active dose.

A smaller tablet may require higher-density excipients or direct-compression grades of microcrystalline cellulose. The tradeoff is that high-density formulations can affect tablet porosity and dissolution. The preferred solution is an optimized blend rather than simply increasing compression force.

What formulations are protected by Sensipar patents?

The historical core composition patent was U.S. Patent No. 6,211,244, which covered calcimimetic compounds including cinacalcet-related chemical matter. Its term expired in 2021, subject to any applicable patent-term adjustment or pediatric extension.[3]

Sensipar's commercial protection also included regulatory exclusivity and other patent rights associated with the active ingredient and clinical uses. Those rights should be separated from current formulation opportunities:

Protection category	Commercial relevance
Active-ingredient and compound patents	Historical barrier; core U.S. protection has expired
Drug-product patents	Must be checked in the current Orange Book for each listed patent
Method-of-use patents	May affect specific indications or dosing claims
Regulatory exclusivity	Has expired for the original U.S. approval
Formulation patents	Relevant only if an unexpired, listed claim covers a specific product
Manufacturing patents	May remain relevant outside the United States or in differentiated processes

An excipient combination that merely reproduces the reference product is unlikely to create durable exclusivity. Commercial value is more likely to come from a technically differentiated dosage form, a new route of administration, or a formulation that supports a new patient population.

What is the Orange Book status of Sensipar?

Sensipar is an approved small-molecule product listed in FDA's Orange Book under NDA 021688. The main commercial patent barrier associated with the original product has expired, allowing ANDA applicants to compete through Paragraph IV or other applicable certification routes.[4]

The strategic implications are:

1. Generic sponsors do not face biosimilar development requirements.
2. A conventional immediate-release tablet can generally be pursued through the ANDA pathway.
3. Any remaining listed patent must be assessed claim by claim, including expiration date, pediatric extension, and whether it covers the proposed generic product.
4. Method-of-use patents may create exposure for a specific indication even when the product itself is no longer broadly blocked.
5. A differentiated formulation may require a 505(b)(2) application rather than an ANDA.

Which companies are challenging Sensipar exclusivity?

Multiple generic companies have entered or pursued the U.S. cinacalcet market after expiration of core protection. FDA's Approved Drug Products with Therapeutic Equivalence Evaluations and Drugs@FDA should be used to identify current ANDA approvals, tentative approvals, sponsors, and therapeutic-equivalence ratings.[4,5]

The competitive field typically includes:

• Large generic manufacturers with dialysis and hospital distribution.
• Specialty generic companies focused on complex or low-volume products.
• Regional suppliers serving government tenders and dialysis networks.
• Contract manufacturers offering low-cost tablet production.

A sponsor's advantage will depend less on basic chemical access and more on manufacturing reliability, validated dissolution, supply continuity, and formulary contracting. Cinacalcet demand is concentrated in chronic-care channels, where shortages can quickly shift purchasing decisions.

When did Sensipar lose exclusivity?

Sensipar lost its principal U.S. small-molecule patent protection in 2021. Generic competition began before or around the end of the core patent term through Paragraph IV litigation and settlement-driven launch arrangements. Amgen reported a sharp decline in Sensipar sales as generic competition entered the U.S. market.[6]

Event	Timing
FDA approval of Sensipar	2004
Commercial growth in dialysis indication	2000s and 2010s
Core U.S. patent expiration	2021
Generic competition	Began before or around core patent expiry
Current market structure	Generic-dominated in the United States

The original product's peak annual sales exceeded $1 billion, creating a large historical revenue pool. That value has shifted from branded sales to generic volume, price competition, and international supply contracts.[6]

What patent litigation and Paragraph IV risks affect cinacalcet?

Cinacalcet litigation risk has historically centered on whether generic products could launch before expiry of Amgen's listed patents. Paragraph IV litigation can trigger a 30-month stay for an ANDA applicant when the innovator sues within the statutory period under the Hatch-Waxman framework.[7]

Key risk categories include:

• Validity challenges against compound or product patents.
• Non-infringement arguments based on the proposed generic formulation.
• Method-of-use carve-outs for protected indications.
• Settlement agreements that establish an agreed launch date.
• At-risk launch exposure before final resolution.
• International proceedings involving different patent terms.

For current market-entry planning, the critical question is no longer whether the original Sensipar franchise is broadly protected. It is whether a proposed product infringes any unexpired, enforceable claim in the target jurisdiction. The FDA Orange Book, ANDA litigation records, and patent-family status should be reviewed together.[4,7]

What commercial opportunities exist for Sensipar excipients and formulations?

Low-risk generic tablet platform

The largest near-term opportunity is a cost-efficient immediate-release tablet using established excipients. The winning platform should deliver:

• Fast and consistent dissolution.
• Low tablet weight.
• Robust compression and coating performance.
• Stable supply of pharmaceutical-grade excipients.
• Competitive cost per tablet.
• Three-strength manufacturing flexibility.

A single formulation architecture across 30 mg, 60 mg, and 90 mg strengths can reduce validation and inventory costs.

Pediatric and geriatric products

The existing tablet is not designed for flexible administration. Potential opportunities include:

• Oral granules.
• Ready-to-use oral suspension.
• Dispersible tablets.
• Mini-tablets.
• Taste-masked liquid dosage forms.

These products would face additional stability, taste, dosing-accuracy, and bioequivalence requirements. A pediatric product could support a 505(b)(2) strategy if it adds a clinically meaningful dosage form rather than simply copying the reference tablet.

Lower-food-dependence formulation

A formulation that produces more consistent exposure with variable meal conditions could have clinical and commercial value. This would require careful pharmacokinetic development because the reference product is taken with food and food materially affects exposure.[1] The opportunity is technically attractive but carries higher regulatory risk than a conventional generic.

Manufacturing and excipient supply

Excipient suppliers can compete through:

• Direct-compression cellulose and starch systems.
• Low-moisture granulation platforms.
• Coating systems with improved color uniformity.
• Lubricant systems that minimize dissolution impact.
• Ready-to-use co-processed excipients.
• Technical support for scale-up and process validation.

The strongest supplier proposition is a validated formulation package that reduces development time and supports consistent dissolution at commercial scale.

How strong is the Sensipar patent estate?

The estate is weak as a barrier to conventional U.S. generic entry because the principal historical patent term has expired and regulatory exclusivity is no longer active. Its residual value is jurisdiction-specific and claim-specific.

Factor	Assessment
Core compound protection	Expired in the United States
Orange Book blocking risk	Primarily dependent on any remaining listed claims
Formulation barrier	Limited for standard immediate-release tablets
Method-of-use barrier	Potentially relevant by indication
Biosimilar barrier	None
Manufacturing barrier	Moderate, driven by dissolution and scale-up
Regulatory barrier	Manageable through ANDA; higher for reformulations
Commercial barrier	Strong price pressure and concentrated buyers

The practical moat is manufacturing execution rather than patent exclusivity.

How does cinacalcet compare with competing hyperparathyroidism products?

Product	Active ingredient	Modality	Competitive position
Sensipar and generics	Cinacalcet	Oral small molecule	Established, genericized, low-cost competition
Parsabiv	Etelcalcetide	Intravenous calcimimetic	Dialysis-center administration; avoids oral adherence
Vitamin D analogs	Various	Oral or injectable	Used for mineral-bone disorder management, often in combination
Parathyroidectomy	Surgical	Procedure	Relevant for selected primary hyperparathyroidism patients
Bisphosphonates or other agents	Various	Oral or injectable	Indication-dependent, not direct substitutes in all settings

Parsabiv, also associated with Amgen, is the closest branded pharmacologic comparator but uses intravenous administration in the dialysis setting. Cinacalcet remains attractive where oral treatment is acceptable and generic pricing is decisive.[8]

What generic launch scenarios exist?

Scenario 1: Commodity immediate-release tablets

This is the most likely market structure. Several suppliers compete on price, availability, and channel access. Excipient differentiation has limited value unless it improves manufacturing yield or reduces product complaints.

Scenario 2: Limited-source supply

If only a small number of manufacturers remain active, reliable production and inventory become more valuable than nominal lowest price. A supplier with validated alternate excipient sources can gain share with dialysis distributors and hospital systems.

Scenario 3: Differentiated oral dosage form

A liquid, dispersible tablet, or taste-masked product could target patients who cannot swallow conventional tablets. This requires more clinical and regulatory work but may support higher pricing and narrower competition.

Scenario 4: International expansion

Patent and regulatory conditions differ by country. Opportunities may exist in markets where generic penetration is low, dialysis capacity is expanding, or local manufacturing is favored. Each market requires separate review of patent term, registration pathway, reference-product requirements, and excipient acceptability.

Key Takeaways

• Sensipar is cinacalcet hydrochloride, an oral immediate-release calcimimetic.
• The reference formulation uses conventional excipients centered on microcrystalline cellulose, pregelatinized starch, povidone, crospovidone, silicon dioxide, magnesium stearate, and film-coating materials.
• The core U.S. patent barrier expired in 2021, making conventional generic entry the primary opportunity.
• Cinacalcet is not a biologic and has no biosimilar risk profile.
• The main technical risks are low solubility, food-dependent exposure, dissolution control, and tablet robustness.
• The strongest near-term opportunity is a low-cost, scalable three-strength generic tablet.
• Higher-value opportunities include pediatric, geriatric, dispersible, liquid, and lower-food-dependence formulations.
• Commercial advantage will depend more on manufacturing reliability and distribution than on broad patent exclusivity.

FAQs

Can Sensipar generics use different excipients?

Yes. An ANDA applicant can use a different excipient composition if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements. Large qualitative and quantitative differences can increase regulatory and development risk.

Is cinacalcet a good candidate for an oral suspension?

It is a technically plausible candidate, particularly for patients who cannot swallow tablets. The main challenges are taste masking, chemical and physical stability, dose uniformity, preservative strategy, and demonstrating comparable exposure.

Does a cinacalcet formulation patent create exclusivity?

Only an unexpired, enforceable patent with claims covering the relevant product or use can create meaningful exclusivity. A formulation patent that is not listed or does not read on the proposed product may have limited ANDA-blocking value.

What excipient issue is most likely to cause generic failure?

Dissolution variability is a leading risk. Lubrication, compression force, active-particle size, granulation conditions, and disintegrant placement can materially affect release and bioequivalence performance.

Is Sensipar still commercially important after generic entry?

Yes, but the value has shifted from branded product sales to generic supply, chronic dialysis demand, contract manufacturing, and differentiated dosage forms. Generic price erosion limits margins, while reliable supply can support share and institutional contracts.

References

1. U.S. Food and Drug Administration. (2023). Sensipar (cinacalcet hydrochloride) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development.
3. U.S. Patent No. 6,211,244. (2001). Calcimimetic compounds.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
6. Amgen Inc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
7. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
8. U.S. Food and Drug Administration. (2017). Parsabiv (etelcalcetide) injection: Prescribing information.